Background: Dextromethorphan (DM), the d-isomer of ... extrapolated to suggest that pregnant women should not use this drug because of the risk of birth defects. We conducted a controlled study ...

Continued treatment with AXS-05, a combination of dextromethorphan and bupropion, significantly reduces the risk for recurrence of Alzheimer’s disease–related agitation, phase 3 results show.

The Gadgets 360 Best Tablets page shows the top-rated tablets reviewed by us in the recent past. The tablets were launched less than 2 years ago, and have received a rating of 8 or above. When you ...

Redmi's latest mobile launch is the Pad SE 8.7. The tablet was launched in 21st August 2024. The tablet comes with a 8.70-inch touchscreen display with a resolution of 800 pixels by 1340 pixels. It ...

NMDA antagonist dextromethorphan is an ingredient found ... However, it has a broader label as unlike J&J's drug it is indicated for use in previously-untreated MDD. Axsome's drug was given ...

While humans have used opioids for their medicinal benefits, the drug has paved the path of both treatment and tragedy.

The 10th-generation Apple iPad, the latest model of Apple’s entry-level tablet, is highlighted in our list of the best iPads as the top mid-range iPad because of its modern design, the switch to ...

Agitated patients are often prescribed antipsychotic medications and sedatives off-label, but this can pose a risk to the ...

'ZDNET Recommends': What exactly does it mean? ZDNET's recommendations are based on many hours of testing, research, and comparison shopping. We gather data from the best available sources ...

If you’re an assiduous notetaker, you know that it’s hard to put a price on a great writing tablet. The best writing and note-taking tablets can streamline your workflow, help you organize ...

For Apple tablets, the 11th generation iPad costs $349 and performs exceptionally well. You can read our review of that model here . Are There Any Bundle Deals That Include Tablet Accessories?

At the recent American Academy of Neurology (AAN) 2025 annual meeting, Axsome Therapeutics (Nasdaq: AXSM) presented promising data for AXS-05 (bupropion + dextromethorphan) in treating agitation ...